{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:49:53Z","timestamp":1792093793495,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.beem.2024.101906","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:41:21Z","timestamp":1716306081000},"page":"101906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine"],"prefix":"10.1016","volume":"38","author":[{"given":"Luiz Eduardo","family":"Wildemberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christhiane","family":"Fialho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f4nica R.","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beem.2024.101906_bib1","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2024.101906_bib2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ecl.2020.05.007","article-title":"Acromegaly: update on management and long-term morbidities","volume":"49","author":"Kasuki","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"10.1016\/j.beem.2024.101906_bib3","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"issue":"11","key":"10.1016\/j.beem.2024.101906_bib4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2024.101906_bib5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"10.1016\/j.beem.2024.101906_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12020-018-1590-8","article-title":"Predictors of surgical outcome and early criteria of remission in acromegaly","volume":"60","author":"Antunes","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101906_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EC-22-0349","article-title":"Starting point for benchmarking outcomes and reporting of pituitary adenoma surgery within the European Reference Network on Rare Endocrine Conditions (Endo-ERN): results from a meta-analysis and survey study","volume":"12","author":"Zamanipoor Najafabadi","year":"2023","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.beem.2024.101906_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11102-017-0791-0","article-title":"Somatostatin receptor ligands in the treatment of acromegaly","volume":"20","author":"Gadelha","year":"2017","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.beem.2024.101906_bib9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The future of somatostatin receptor ligands in acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2024.101906_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","article-title":"Consensus on criteria for acromegaly diagnosis and remission","volume":"27","author":"Giustina","year":"2024","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.beem.2024.101906_bib11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12020-021-02766-2","article-title":"GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil","volume":"74","author":"Manosso","year":"2021","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.beem.2024.101906_bib12","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s12325-020-01600-x","article-title":"Patient and healthcare provider perspectives of first-generation somatostatin analogs in the management of neuroendocrine tumors and acromegaly: a systematic literature review","volume":"38","author":"Cella","year":"2021","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.beem.2024.101906_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"10.1016\/j.beem.2024.101906_bib14","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1210\/jc.2008-0019","article-title":"Gluteal nodules in patients with metastatic midgut carcinoid disease treated with depot somatostatin analogs","volume":"93","author":"Debono","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.beem.2024.101906_bib15","doi-asserted-by":"crossref","first-page":"e3644","DOI":"10.1210\/clinem\/dgac385","article-title":"IGF-I variability over repeated measures in patients with acromegaly under long-acting somatostatin receptor ligands","volume":"107","author":"Maione","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2024.101906_bib16","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.beem.2024.101906_bib17","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2024.101906_bib18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","article-title":"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2024.101906_bib19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bcp.12698","article-title":"Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers","volume":"80","author":"Tiberg","year":"2015","journal-title":"Br J Clin Pharm"},{"issue":"2","key":"10.1016\/j.beem.2024.101906_bib20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00280-018-3734-1","article-title":"Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study","volume":"83","author":"Pavel","year":"2019","journal-title":"Cancer Chemother Pharm"},{"issue":"Suppl 1","key":"10.1016\/j.beem.2024.101906_bib21","article-title":"THU070 randomized, placebo-controlled phase 3 trial protocol assessing the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly","volume":"7","author":"Ferone","year":"2023","journal-title":"J Endocr Soc"},{"issue":"2","key":"10.1016\/j.beem.2024.101906_bib22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11102-021-01201-z","article-title":"Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers","volume":"25","author":"Madan","year":"2022","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.beem.2024.101906_bib23","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41467-023-36673-z","article-title":"Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine","volume":"14","author":"Zhao","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.beem.2024.101906_bib24","article-title":"New treatments for acromegaly in development","author":"Gadelha","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101906_bib25","series-title":"in Endocrine Abstracts","article-title":"Absolute oral bioavailability and absorption, metabolism, excretion of [14C]-Labeled paltusotine (CRN00808), an orally bioavailable, nonpeptide, selective, somatostatin receptor 2 (sst2) biased agonist for the treatment of acromegaly","author":"Madan","year":"2020"},{"key":"10.1016\/j.beem.2024.101906_bib26","series-title":"in J Endocr Soc","article-title":"SAT628 Effect Of Hepatic Impairment On The Pharmacokinetics, Safety, And Tolerability Of Oral Paltusotine, A Non-peptide, Selective Somatostatin Receptor Subtype 2 Agonist","author":"Luo","year":"2023"},{"key":"10.1016\/j.beem.2024.101906_bib27","series-title":"in Endocrine Abstracts","article-title":"Long-term efficacy and safety of oral, once-daily paltusotine treatment in acromegaly: Two-year interim results from the ACROBAT Advance study","author":"Randeva","year":"2022"},{"issue":"5","key":"10.1016\/j.beem.2024.101906_bib28","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1210\/clinem\/dgac643","article-title":"ACROBAT edge: safety and efficacy of switching injected SRLs to oral paltusotine in patients with acromegaly","volume":"108","author":"Gadelha","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2024.101906_bib29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s41687-023-00541-7","article-title":"Development and evaluation of the acromegaly symptom diary","volume":"7","author":"Martin","year":"2023","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.beem.2024.101906_bib30","series-title":"in J Endocr Soc","author":"Gadelha","year":"2023"},{"issue":"Supplement_1","key":"10.1016\/j.beem.2024.101906_bib31","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab048.1068","article-title":"Pharmacokinetics and safety of an improved oral formulation of paltusotine, a selective, non-peptide somatostatin receptor 2 (SST2) AGonist for the Treatment of Acromegaly","volume":"5","author":"Luo","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.beem.2024.101906_bib32","article-title":"Paltusotine maintains IGF-1, GH, and symptom control in patients with acromegaly switched from injected octreotide or lanreotide monotherapy: Topline results from PATHFNDR-1, a phase 3, randomized, double-blind, placebo-controlled, multicenter study","author":"Gadelha","year":"2023","journal-title":"Endocr Abstr"},{"key":"10.1016\/j.beem.2024.101906_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fendo.2017.00040","article-title":"Predictors of quality of life in acromegaly: no consensus on biochemical parameters","volume":"8","author":"Geraedts","year":"2017","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2024.101906_bib34","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/cen.13331","article-title":"Impaired quality of life in patients with treated acromegaly despite long\u2010term biochemically stable disease: results from a 5\u2010years prospective study","volume":"86","author":"Kyriakakis","year":"2017","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2024.101906_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.627711","article-title":"Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands","volume":"12","author":"Fleseriu","year":"2021","journal-title":"Front Endocrinol"},{"issue":"7","key":"10.1016\/j.beem.2024.101906_bib36","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T22:47:49Z","timestamp":1721342869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X24000605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1521690X24000605"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2024.101906","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2024.101906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101906"}}